Divi’s Labs (DIVI), in addition to having a robust base business, is enhancing its product offerings in the generic API space – at least sixteen molecules are under various phases of development and ...

Divi's Laboratories, India's largest API (Active Pharmaceutical Ingredient) manufacturer, sits amid a changing landscape within the global pharmaceutical universe. The growth levers for Divi’s are ...

The FDA, which last month banned APIs coming from a Divi’s Laboratories plant in India, has followed that up with a warning letter that savages the facility for refusing to give inspectors records ...

Divi’s Laboratories share price closed at Rs 3708, up Rs 9 or 0.25%. Divi’s Laboratories share price moved from Rs 3610 to Rs ...

The pharmaceutical industry has been traditionally slow in embracing new technologies, but Divi’s Laboratories is showing the way forward. Recently, this Hyderabad-based firm zeroed in on Juniper ...

Nov 7 (Reuters) - Indian drugmaker Divi's Laboratories (DIVI.NS), opens new tab reported second-quarter profit above analysts' estimates on Friday, helped by its business that focuses on customised ...

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...

Divi’s Laboratories Ltd reported 40.84% increase in revenues yoy for the Q4FY22 quarter on consolidated basis at Rs2,518.44 crore. On a sequential basis, revenues were up for the quarter by 1.01%.

Divi’s Laboratories reported 46.54% yoy rise in total sales revenues for the Dec-21 quarter on consolidated basis at Rs2,493cr. On a sequential basis, the revenues were up by 25.45%. During the ...